Reportedly, the board of biotech behemoth Amgen (AMGN) announced a $2.13 per share dividend for the first quarter of 2023, payable on March 8, 2023, to all stockholders as of February 15, 2023. The dividend represents a 10% increase from its previous four quarters.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.
